GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (7)
  • Nakagawa, Yoshihisa  (7)
  • 1
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 96, No. 1 ( 2020-07), p. 42-51
    Abstract: To assess long‐term outcomes after percutaneous coronary intervention (PCI) with drug‐eluting stent only compared with coronary artery bypass grafting (CABG) in patients with triple‐vessel disease. Background Selection between PCI and CABG is still a clinically relevant issue in the management of patients with multi‐vessel coronary artery disease. Methods Among 15,939 patients enrolled in the CREDO‐Kyoto PCI/CABG registry/cohort‐2, the current study population consisted of 2,193 patients who underwent elective multi‐vessel coronary revascularization including left anterior descending coronary artery (LAD) either by PCI with sirolimus‐eluting stent (SES) only ( N = 945) or CABG ( N = 1,248). Results The cumulative 5‐year incidence of and the adjusted risk for the primary outcome measure (a composite of all‐cause death, myocardial infarction [MI], or stroke) were not significantly different between PCI and CABG groups (22.6% vs. 23.0%, p = .40, and HR: 1.13, 95%CI: 0.91–1.40, p = .26). The risk of PCI relative to CABG for all‐cause death and stroke was also insignificant (HR: 1.19, 95%CI: 0.92–1.53, p = .19; HR: 0.89, 95%CI: 0.62–1.27, p = .51). The adjusted 5‐year risk for MI, hospitalization for heart failure (HF), any coronary revascularization and major bleeding was significantly different between the groups (HR: 1.59, 95%CI: 1.10–2.30, p = .01; HR: 1.49, 95%CI: 1.05–2.11, p = .02; HR: 3.70, 95%CI: 2.91–4.70, p   〈  .0001; HR: 0.18, 95%CI: 0.14–0.22, p   〈  .0001). Conclusions In patients who underwent coronary revascularization for multiple vessels including LAD, PCI using SES as compared with CABG was associated with a comparable 5‐year risk for death/MI/stroke as well as for mortality, but with a markedly higher risk for any coronary revascularization.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 97, No. 6 ( 2021-05)
    Abstract: To evaluate utility of the complex percutaneous coronary intervention (PCI) criteria in real‐world practice. Background Applicability of procedural complexity criteria for risk stratification has not been adequately evaluated in real‐world practice. Methods Among 13,087 patients undergoing first PCI in the CREDO‐Kyoto registry cohort‐2, the study population consisted of 7,871 patients after excluding patients with acute myocardial infarction and those without stent implantation. Complex PCI was defined as PCI, which fulfills at least one of the followings: three vessels treated, 〉  = 3 stents implanted, 〉  = 3 lesions treated, bifurcation with two stents, 〉 60 mm total stent lengths, and target of chronic total occlusion. Results The cumulative incidences of and adjusted risks for the primary ischemic (myocardial infarction/ischemic stroke), and bleeding (GUSTO moderate/severe) endpoints were significantly higher in patients with complex PCI ( N  = 2,777 [35%]) than in those with noncomplex PCI ( N  = 5,094 [65%]) (15.4% vs. 10.9%, log‐rank p   〈  .001; odds ratio (OR): 1.53, 95% confidence interval (CI): 1.31–1.79, p   〈  .001, and 11.9% vs. 9.9%, log‐rank p  = .004; OR: 1.24, 95% CI: 1.05–1.46, p  = .01). In the 30‐day landmark analysis, the higher risks of patients with complex PCI for ischemic and major bleeding events were only seen within 30 days after PCI (ischemic; within 30 days: HR: 2.19, 95% CI: 1.79–2.69, p   〈  .001; beyond 30 days: HR: 1.11, 95% CI: 0.92–1.34, p  = .26, and bleeding; within 30 days: HR: 1.56, 95% CI: 1.13–2.16, p  = .007; beyond 30 days: HR: 1.11, 95% CI: 0.94–1.31, p  = .22). Conclusions Patients with complex PCI as compared with patients with noncomplex PCI had a higher risk for both ischemic and bleeding events mainly within 30 days after PCI.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 92, No. 3 ( 2018-09), p. 455-463
    Abstract: We aimed to investigate the effect of chronic total occlusion (CTO) in non‐infarct‐related artery (IRA) on short‐ and long‐term mortality in ST‐segment elevation myocardial infarction (STEMI) patients complicated by cardiogenic shock (CS). Background Previous studies show contradictory results about the clinical effect of CTO in non‐IRA on short‐term mortality in STEMI patients with CS. Methods From the CREDO‐Kyoto AMI registry enrolling 5429 patients, the current study population consisted of 313 STEMI patients with multivessel disease complicated by CS who underwent primary PCI for the nonleft main coronary artery culprit lesion within 24 hr after onset. They were divided according to the presence of CTO (CTO group: N  = 100 and non‐CTO group: N  = 213). Results Hemodynamic compromise was more profound in the CTO group as suggested by the more frequent use of intra‐aortic balloon pumping and/or extracorporeal membrane oxygenation. Infarct size estimated by the peak creatine phosphokinase level was larger in the CTO group than in the non‐CTO group. The cumulative 30‐day and 5‐year incidences of all‐cause death were significantly higher in the CTO group than in the non‐CTO group (34.0% vs 18.0%, P  = 0.001, and 64.5% vs 46.0%, P  = 0.0001). After adjusting for confounders, the excess risk of the CTO group relative to the non‐CTO group for all‐cause death remained significant both at 30 days and at 5 years (hazard ratio [HR] : 2.05, 95% confidence interval [CI]: 1.27–3.29, P  = 0.003, and HR: 1.90, 95% CI: 1.34–2.69, P  = 0.0004). Conclusions In STEMI patients complicated by CS, CTO in non‐IRA was associated with increased 30‐day and 5‐year mortality.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: ESC Heart Failure, Wiley, Vol. 10, No. 3 ( 2023-06), p. 1948-1960
    Abstract: Several studies demonstrated that tricuspid regurgitation (TR) is associated with poor clinical outcomes. However, data on patients with TR who experienced acute heart failure (AHF) remains scarce. The purpose of this study is to evaluate the association between TR and clinical outcomes in patients admitted with AHF, using a large‐scale Japanese AHF registry. Methods and results The current study population consisted of 3735 hospitalized patients due to AHF in the Kyoto Congestive Heart Failure (KCHF) registry. TR grades were assessed according to the routine clinical practice at each participating centre. We compared the baseline characteristics and outcomes according to the severity of TR. The primary outcome was all‐cause death. The secondary outcome was hospitalization for heart failure (HF). The median age of the entire study population was 80 (interquartile range: 72–86) years. One thousand two hundred five patients (32.3%) had no TR, while mild, moderate, and severe TR was found in 1537 patients (41.2%), 776 patients (20.8%), and 217 patients (5.8%), respectively. Pulmonary hypertension, significant mitral regurgitation, and atrial fibrillation/flutter were strongly associated with the development of moderate/severe of TR, while left ventricular ejection fraction 〈 50% was inversely associated with it. Among 993 patients with moderate/severe TR, the number of patients who underwent surgical intervention for TR within 1 year was only 13 (1.3%). The median follow‐up duration was 475 (interquartile range: 365–653) days with 94.0% follow‐up at 1 year. As the TR severity increased, the cumulative 1 year incidence of all‐cause death and HF admission proportionally increased ([14.8%, 20.3%, 23.4%, 27.0%] and [18.9%, 23.0%, 28.5%, 28.4%] in no, mild, moderate, and severe TR, respectively). Compared with no TR, the adjusted risks of patients with mild, moderate, and severe TR were significant for all‐cause death (hazard ratio [95% confidence interval]: 1.20 [1.00–1.43] , P  = 0.0498, 1.32 [1.07–1.62], P  = 0.009, and 1.35 [1.00–1.83], P  = 0.049, respectively), while those were not significant for hospitalization for HF (hazard ratio [95% confidence interval]: 1.16 [0.97–1.38] , P  = 0.10, 1.19 [0.96–1.46], P  = 0.11, and 1.20 [0.87–1.65], P  = 0.27, respectively). The higher adjusted HRs of all the TR grades relative to no TR were significant for all‐cause death in patients aged 〈 80 years, but not in patients aged ≥80 years with significant interaction. Conclusions In a large Japanese AHF population, the grades of TR could successfully stratify the risk of all‐cause death. However, the association of TR with mortality was only modest and attenuated in patients aged 80 or more. Further research is warranted to evaluate how to follow up and manage TR in this elderly population.
    Type of Medium: Online Resource
    ISSN: 2055-5822 , 2055-5822
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2814355-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: ESC Heart Failure, Wiley, Vol. 7, No. 5 ( 2020-10), p. 2485-2493
    Abstract: The association between sex and long‐term outcome in patients hospitalized for acute decompensated heart failure (ADHF) has not been fully studied yet in Japanese population. The aim of this study was to determine differences in baseline characteristics and management of patients with ADHF between women and men and to compare 1‐year outcomes between the sexes in a large‐scale database representing the current real‐world clinical practice in Japan. Methods and results Kyoto Congestive Heart Failure registry is a prospective cohort study enrolling consecutive patients hospitalized for ADHF in Japan among 19 centres. Baseline characteristics, clinical presentation, management, and 1‐year outcomes were compared between men and women. A total of 3728 patients who were alive at discharge constituted the current study population. There were 1671 women (44.8%) and 2057 men. Women were older than men [median (IQR): 83 (76–88) years vs. 77 (68–84) years, P   〈  0.0001]. Hypertensive and valvular heart diseases were more prevalent in women than in men (28.0% vs. 22.5%, P  = 0.0001; and 26.9% vs. 14.0%, P   〈  0.0001, respectively), whereas ischaemic aetiology was less prevalent in women than in men (20.0% vs. 32.5%, P   〈  0.0001). Women less often had reduced left ventricular ejection fraction ( 〈 40%) than men (27.5% vs. 45.1%, P   〈  0.0001). The cumulative incidence of all‐cause death or hospitalization for heart failure was not significantly different between women and men (33.6% vs. 34.3%, P  = 0.71), although women were substantially older than men. After multivariable adjustment, the risk of all‐cause death or hospitalization for heart failure was significantly lower among women (adjusted hazard ratio: 0.84, 95% confidence interval: 0.74–0.96, P  = 0.01). Conclusions Women with heart failure were older and more often presented with preserved EF with a non‐ischaemic aetiology and were associated with a reduced adjusted risk of 1‐year mortality compared with men in the Japanese population.
    Type of Medium: Online Resource
    ISSN: 2055-5822 , 2055-5822
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2814355-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 102, No. 4 ( 2023-10), p. 594-607
    Abstract: New‐generation drug‐eluting stents (DES) achieved technological innovations and reported clinical advantages as compared with first‐generation DES in clinical trials with 3–5 years follow‐up. However, detailed clinical outcome data in very long‐term follow‐up is still scarce. Objectives To evaluate 10‐year clinical outcomes after first‐ and new‐generation DES implantation. Methods In this extende follow‐up study of the RESET, which is a largest randomized trial comparing everolimus‐eluting stent (EES) with Sirolimus‐eluting stent (SES), the study population consisted of 2892 patients from 84 centers. The primary efficacy and safety endpoints were target lesion revascularization (TLR) and a composite of death or myocardial infarction (MI), respectively. Complete 10‐year follow‐up was achieved in 87.9% of patients. Results Cumulative 10‐year incidences of TLR and non‐TLR were not significantly different between EES and SES (13.9% vs. 15.7%, Log‐rank p  = 0.20, and 33.4% vs. 31.3%, Log‐rank p  = 0.30). The cumulative 10‐year incidence of death/MI was also not significantly different between the groups (32.5% vs. 34.4%, Log‐rank p  = 0.18). Cumulative 10‐year incidence of definite stent thrombosis was numerically lower in EES than in SES (1.0% vs. 1.7%, Log‐rank p  = 0.16). The lower risk of EES relative to SES was significant for a composite endpoint of target lesion failure (TLF: 19.6% vs. 24.9%, Log‐rank p  = 0.001) and target vessel failure (TVF: 26.7% vs. 31.4%, Log‐rank p  = 0.006). Conclusion During 10‐year of follow‐up, the risks for primary efficacy and safety endpoints were not significantly different between new‐generation EES and first‐generation SES, although EES compared with SES was associated with a lower risk for composite endpoints such as TLF and TVF.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: ESC Heart Failure, Wiley, Vol. 9, No. 3 ( 2022-06), p. 1920-1930
    Abstract: There is a scarcity of data on the post‐discharge prognosis in acute heart failure (AHF) patients with a low‐income but receiving public assistance. The study sought to evaluate the differences in the clinical characteristics and outcomes between AHF patients receiving public assistance and those not receiving public assistance. Methods and results The Kyoto Congestive Heart Failure registry was a physician‐initiated, prospective, observational, multicentre cohort study enrolling 4056 consecutive patients who were hospitalized due to AHF for the first time between October 2014 and March 2016. The present study population consisted of 3728 patients who were discharged alive from the index AHF hospitalization. We divided the patients into two groups, those receiving public assistance and those not receiving public assistance. After assessing the proportional hazard assumption of public assistance as a variable, we constructed multivariable Cox proportional hazard models to estimate the risk of the public assistance group relative to the no public assistance group. There were 218 patients (5.8%) receiving public assistance and 3510 (94%) not receiving public assistance. Patients in the public assistance group were younger, more frequently had chronic coronary artery disease, previous heart failure hospitalizations, current smoking, poor medical adherence, living alone, no occupation, and a lower left ventricular ejection fraction than those in the no public assistance group. During a median follow‐up of 470 days, the cumulative 1 year incidences of all‐cause death and heart failure hospitalizations after discharge did not differ between the public assistance group and no public assistance group (13.3% vs. 17.4%, P  = 0.10, and 28.3% vs. 23.8%, P  = 0.25, respectively). After adjusting for the confounders, the risk of the public assistance group relative to the no public assistance group remained insignificant for all‐cause death [hazard ratio (HR), 0.97; 95% confidence interval (CI), 0.69–1.32; P  = 0.84]. Even after taking into account the competing risk of all‐cause death, the adjusted risk within 180 days in the public assistance group relative to the no public assistance group remained insignificant for heart failure hospitalizations (HR, 0.93; 95% CI, 0.64–1.34; P  = 0.69), while the adjusted risk beyond 180 days was significant (HR, 1.56; 95% CI, 1.07–2.29; P  = 0.02). Conclusions The AHF patients receiving public assistance as compared with those not receiving public assistance had no significant excess risk for all‐cause death at 1 year after discharge or a heart failure hospitalization within 180 days after discharge, while they did have a significant excess risk for heart failure hospitalizations beyond 180 days after discharge. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02334891 (NCT02334891) and https://upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000017241 (UMIN000015238)
    Type of Medium: Online Resource
    ISSN: 2055-5822 , 2055-5822
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2814355-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...